News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Drugs RG1678 Show Promise Treating Schizophrenia, Blood Cancer in Mid-Stage Studies
December 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH Dec 6 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) presented the results of studies on two drugs in mid-stage development that may go some way towards addressing concerns about the strength of the company's drug pipeline.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
Roche
MORE ON THIS TOPIC
Neuroscience
AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data
April 23, 2026
·
4 min read
·
Tristan Manalac
Insights
The next era of diabetes management
April 23, 2026
·
1 min read
·
Jennifer C. Smith-Parker
rare diseases
Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision
April 22, 2026
·
2 min read
·
Nick Paul Taylor
Podcast
Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win
April 22, 2026
·
1 min read
·
Heather McKenzie
